

Instance: composition-en-d5d8894da2fa70f6a957a74ada445d1e
InstanceOf: CompositionUvEpi
Title: "Composition for xadago Package Leaflet"
Description:  "Composition for xadago Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - xadago"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Xadago is and what it is used for  </li>
<li>What you need to know before you take Xadago </li>
<li>How to take Xadago </li>
<li>Possible side effects  </li>
<li>How to store Xadago </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What xadago is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What xadago is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Xadago is a medicine that contains the active substance safinamide. It acts to increase the level of a 
substance called dopamine in the brain, which is involved in the control of movement and is present in 
reduced amounts in the brain of patients with Parkinson s disease. Xadago is used for the treatment of 
Parkinson s disease in adults.  </p>
<p>In mid- to late-stage patients experiencing sudden switches between being  ON  and able to move and 
being  OFF  and having difficulties moving about, Xadago is added to a stable dose of the medicine 
called levodopa alone or in combination with other medicines for Parkinson s disease. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take xadago"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take xadago"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Xadago 
- If you are allergic to safinamide or any of the other ingredients of this medicine (listed in 
section 6).<br />
- If you are taking any of the following medicines:</p>
<ul>
<li>Monoamine oxidase (MAO) inhibitors such as selegiline, rasagiline, moclobemide, 
phenelzine, isocarboxazid, tranylcypromine (e.g. for treatment of Parkinson s disease or 
depression, or used for any other condition).  </li>
<li>Pethidine (a strong pain killer).<br />
You must wait at least 7 days after stopping Xadago treatment before starting treatment with 
MAO inhibitors or pethidine. </li>
<li>If you have been told that you have severe liver problems  </li>
<li>If you have an eye condition which might put you at risk of potential damage to your retina (the 
light sensitive layers at the back of your eyes), e.g. albinism (lack of pigment in your skin and 
eyes), retinal degeneration (loss of cells from light sensitive layer at the back of the eye), or 
uveitis (inflammation inside of the eye), inherited retinopathy (inherited disorders of the vision), 
or severe progressive diabetic retinopathy (a progressive decrease of the vision due to diabetes). </li>
</ul>
<p>Warnings and precautions<br />
Talk to your doctor before taking Xadago<br />
- If  you have liver problems<br />
- Patients and carers should be made aware that certain compulsive behaviours such as 
compulsions, obsessive thoughts, pathological gambling, increased libido, hypersexuality, 
impulsive behaviour and compulsive spending or buying have been reported with other 
medicines for Parkinson s disease.<br />
- Uncontrollable jerky movements may occur or worsen when Xadago is used together with 
levodopa.  </p>
<p>Children and adolescents 
Xadago is not recommended for use in children and adolescents, below 18 years old due to the lack of 
data on safety and efficacy in this population. </p>
<p>Other medicines and Xadago 
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other 
medicines. Ask your doctor for advice before taking any of the following medicines together with 
Xadago:</p>
<ul>
<li>Cold or cough remedies containing dextromethorphan, ephedrine or pseudoephedrine </li>
<li>Medicines called selective serotonin reuptake inhibitors (SSRIs) typically used to treat anxiety 
disorders, and some personality disorders (e.g. fluoxetine or fluvoxamine) </li>
<li>Medicines called serotonin norepinephrine reuptake inhibitors (SNRIs), used in the treatment of 
major depression and other mood disorders, such as venlafaxine </li>
<li>Medicines for high cholesterol such as rosuvastatin, pitavastatin, pravastatin </li>
<li>Fluoroquinolone antibiotic such as ciprofloxacin </li>
<li>Medicines that affect the immune system such as methotrexate  </li>
<li>Medicines to treat metastatic carcinoma such as topotecan </li>
<li>Medicine to treat pain and inflammation such as diclofenac </li>
<li>Medicines to treat type 2 diabetes such as glyburide, metformin </li>
<li>Medicines to treat virus infection such as aciclovir, ganciclovir </li>
</ul>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine.  </p>
<p>Pregnancy<br />
Xadago should not be used during pregnancy or by women of childbearing potential not practicing 
adequate contraception. </p>
<p>Breast Feeding 
Xadago is likely to be excreted in breast milk. Xadago should not be used during breast-feeding. </p>
<p>Driving and using machines 
Somnolence and dizziness may occur during safinamide treatment; you should be cautious about 
operating hazardous machines or driving, until you are reasonably certain that Xadago does not affect 
you in any way.  </p>
<p>Ask your doctor for advice prior to driving or using machines. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take xadago"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take xadago"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not 
sure. </p>
<p>The recommended starting dose of Xadago is one 50 mg tablet that may be increased to one 100 mg 
tablet, taken once daily preferably in the morning by mouth with water. Xadago may be taken with or 
without food.  </p>
<p>If you suffer from moderately reduced liver function, you should not take more than 50 mg a day; your 
doctor will advise if this applies to you. </p>
<p>If you take more Xadago than you should 
If you have taken too many Xadago tablets, you may develop raised blood pressure, anxiety, 
confusion, forgetfulness, sleepiness, lightheadedness; feel sick or be sick; dilated pupils or develop 
involuntary jerky movements. Contact your doctor immediately and take the Xadago pack with you.  </p>
<p>If you forget to take Xadago<br />
Do not take a double dose to make up for a forgotten dose. Skip the missed dose and take the next 
dose at the time you normally take it.  </p>
<p>If you stop taking Xadago 
Do not stop taking Xadago without first talking to your doctor.<br />
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />
Seek medical advice in case of hypertensive crisis (very high blood pressure, collapse), neuroleptic 
malignant syndrome (confusion, sweating, muscle rigidity, hyperthermia, increase level of enzyme 
creatine kinase in your blood), serotonin syndrome (confusion, hypertension, muscle stiffness, 
hallucinations), and hypotension. </p>
<p>The following side effects have been reported in patients at a mid- to late-stage of Parkinson s disease 
(patients taking safinamide as add-on to levodopa alone or in combination with other medicines for 
Parkinson s disease): </p>
<p>Common (may affect up to 1 in 10 people): insomnia, difficulty in performing voluntary movements, 
feeling sleepy, dizziness, headache, worsening of Parkinson s disease, clouding of the lens of the eye, 
fall in blood pressure when rising to a standing position, nausea, falling.  </p>
<p>Uncommon (may affect up to 1 in 100 people): urine infection, skin cancer, low iron in your blood, 
low white cell count, red blood cell abnormality, decreased appetite, high fat in blood, increased 
appetite, high blood sugar, seeing things that are not there, feeling sad, abnormal dreams, fear and 
worry, confusional state, mood swings , increased interest in sex, abnormal thinking and perception, 
restlessness, sleep disorder, numbness, unsteadiness, loss of sensation, sustained abnormal muscle 
contraction, head discomfort, difficulty in speaking, fainting, memory impairment, blurring of vision, 
blind spot, double vision, aversion to light, disorders of the light sensitive layer at the back of your 
eye, redness of the eyes, increased pressure in the eye, sensation of room spinning, feeling of heart 
beating, fast heartbeat, irregular heartbeat, slowed heartbeat , high blood pressure, low blood pressure, 
veins that have become large and twisted, cough, difficult breathing, runny nose, constipation, 
heartburn, vomiting, dry mouth, diarrhoea, abdominal pain, burning stomach, wind, feeling full, 
drooling, mouth ulcer, sweating, itching, sensitive to light, redness of the skin, back pain, joint pain, 
cramps, stiffness, pain in legs or arms, muscle weakness, sensation of heaviness, increased urination at 
night, pain upon urination, difficulty in having sex in males, fatigue, feeling weak, unsteady walking, 
swelling of your feet, pain, feeling hot, weight loss, weight gain, abnormal blood tests, high fat in your 
blood, increased sugar in your blood, abnormal ECG, liver function test abnormal, abnormal urine 
tests, blood pressure decreased, blood pressure increased, abnormal eye test, fracture of your foot.  </p>
<p>Rare (may affect up to 1 in 1000 people): pneumonia, skin infection, sore throat, nasal allergy, tooth 
infection, viral infection, non-cancerous skin conditions/growth, white blood cell abnormalities, severe 
loss of weight and weakness, increased potassium in blood, uncontrollable urges, clouding of 
consciousness, disorientation, wrong perception of images, reduced interest in sex, thoughts that you 
cannot get rid of, feeling that someone is out to get you, premature ejaculation, uncontrollable urge to 
sleep, fear of social situations, thoughts of suicide, clumsiness, easily distracted, loss of taste, 
weak/slow reflexes, radiating pain in the legs, continuous desire to move your legs, feeling sleepy, eye 
abnormalities, progressive diminution of vision due to diabetes, increased tears, night blindness, cross 
eyed, heart attack, tightening/narrowing of blood vessel, severe high blood pressure, tightening of the 
chest, difficulty in speaking, difficulty in/painful swallowing, peptic ulcer, retching, stomach bleeding, 
jaundice, loss of hair, blister, skin allergy, skin conditions, bruising, scaly skin, night sweats, pain of 
skin, discolouration of the skin, psoriasis, flaky skin, inflammation of spinal joints due to an 
autoimmune disorder, pain in your sides, swelling of joints, musculoskeletal pain, muscular pain, neck 
pain, joint pain, cyst in the joint, uncontrollable urge to urinate, increased urination, passing of pus 
cells in urine, urinary hesitation, prostate problem, breast pain, drug effect decreased, drug intolerance, 
feeling cold, feeling unwell, fever, dryness of skin, eye and mouth, abnormal blood tests, heart 
murmur, abnormal heart tests, bruising/swelling after injury, blood vessel blockage due to fat, head 
injury, mouth injury, skeletal injury, gambling. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store xadago"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store xadago"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.  </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after  EXP <br />
The expiry date refers to the last day of that month.  </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Xadago contains<br />
- The active substance is safinamide. Each tablet contains 50 mg or 100 mg of safinamide (as 
methansulfonate).<br />
- The other ingredients are:</p>
<ul>
<li>Tablet core: microcrystalline cellulose, crospovidone type A, magnesium stearate, silica 
colloidal anhydrous  </li>
<li>Tablet coating: hypromellose, macrogol (6000), titanium dioxide (E171), iron oxide red 
(E172), mica (E555). </li>
</ul>
<p>What Xadago looks like and contents of the pack 
Xadago 50 mg are orange to copper, round, biconcave film-coated tablets of 7 mm diameter with 
metallic gloss, embossed with  50  on one side of the tablet. </p>
<p>Xadago 100 mg are orange to copper, round, biconcave film-coated tablets 9 mm diameter with 
metallic gloss, embossed with  100  on one side of the tablet.  </p>
<p>Xadago is supplied in packs containing 14, 28, 30, 90 or 100 film coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder  </p>
<p>Zambon S.p.A. 
Via Lillo del Duca 20091 Bresso (MI) 
Italy 
Tel: +39 02665Fax: +39 02 66501Email: info.zambonspa@zambongroup.com </p>
<p>Manufacturer </p>
<p>Catalent Germany Schorndorf GmbH 
Steinbeisstrasse 2 
D- 73614 Schorndorf 
Germany </p>
<p>Zambon S.p.A. 
Via della Chimica, 9 
36100 Vicenza 
Italy </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien/ 
Luxembourg/Luxemburg 
Zambon N.V./S.A.<br />
T l/Tel: + 32 2 777 02 France 
Zambon France S.A. 
T l: + 33 (0)1 58 04 41  / Eesti/<br />
Ireland/ sland/ /Latvija/ Malta/Polska/ 
Rom nia/ / United Kingdom (Northern Ireland) <br />
Zambon S.p.A. 
Te ./Tel/ /S mi: + 39 02665Italia 
Zambon Italia S.r.l. 
Tel: + 39 02665Danmark/Norge/Suomi/Finland/Sverige 
Zambon Sweden, Filial of Zambon Nederland B.V. 
Tlf/Puh/Tel: + 46 10 33 50 Nederland 
Zambon Nederland B.V. 
Tel: + 31 (0) 20 3085Deutschland/ sterreich 
Zambon GmbH 
Tel: 00800 92626Portugal 
Zambon - Produtos Farmac uticos, Lda. 
Tel: + 351 217 600 952 / 217 600 Espa a 
Zambon, S.A.U. 
Tel: + 34 93 544 64 Hrvatska/Slovenija 
SALUS, Veletrgovina, d.o.o. 
Tel: + 386 1 5899  esk  republika 
Desitin Pharma spol. s r.o. 
Tel: + 420 222 245 Slovensk  republika 
Desitin Pharma s.r.o.<br />
Tel: + 421 2 5556 3<br />
Innovis Pharma A.E.B.E. 
 :+ 30 216 200 5Magyarorsz g<br />
Richter Gedeon Nyrt. 
Tel.: +36 1 505 7Lietuva 
UAB  Norameda <br />
Tel: + 370 5 2306This leaflet was last revised in . </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      





                      
Instance: bundlepackageleaflet-en-d5d8894da2fa70f6a957a74ada445d1e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for xadago Package Leaflet for language en"
Description: "ePI document Bundle for xadago Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-d5d8894da2fa70f6a957a74ada445d1e"
* entry[0].resource = composition-en-d5d8894da2fa70f6a957a74ada445d1e
                      
                      